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bjectives This study sought to develop a tool for predicting an individual’s risk of mortality fol-
owing rescue percutaneous coronary intervention (PCI).
ackground Although ﬁbrinolytic therapy is appropriate and improves survival for certain ST-segment
levation myocardial infarction patients, a substantial proportion suffer ongoing myocardial ischemia, a
lass I indication for emergent percutaneous coronary intervention (rescue PCI).
ethods Using the National Cardiovascular Data Registry (NCDR), rescue PCI was deﬁned as non-
lective PCI following failed ﬁbrinolysis in patients with continuing or recurrent myocardial ischemia.
ultivariable logistic regression was used to determine mortality predictors and the C-statistic for
odel discrimination. The NCDR-RESCUE (Real-World Estimator of Survival in Catheterized STEMI Pa-
ients Following Unsuccessful Earlier Fibrinolysis) score was developed using a shortened list of 6
re-angiographic variables and 70% of the cohort; performance was subsequently validated against
he remaining 30%.
esults Among 166,516 PCI procedures on patients with an admission diagnosis of ST-segment
levation myocardial infarction, 8,007 (4.8%) represented rescue PCI. In-hospital mortality occurred in
64 (5.8%). Factors in the ﬁnal model were age, glomerular ﬁltration rate, history of congestive heart
ailure, insulin-treated diabetes, cardiogenic shock, and salvage status. The NCDR-RESCUE score ef-
ectively segregated individuals into 6 clinically meaningful risk categories, with 0.4% (0.0% to 1.3%),
.6% (0.9% to 2.4%), 7.6% (5.3% to10.4%), 27.5% (20.7% to 35.1%), 64.2% (49.8% to 76.9%), or 100%
59.0% to 100.0%) risk, respectively, of in-hospital mortality (mean  95% conﬁdence interval,
-index  0.88, Hosmer-Lemeshow p  0.898).
onclusions In-hospital mortality risk among individuals undergoing rescue PCI varies from minimal
o extreme and can be easily calculated using the NCDR-RESCUE score. This information can be of
alue in counseling patients, families, and referring caregivers. (J Am Coll Cardiol Intv 2011;4:
2–50) © 2011 by the American College of Cardiology Foundation
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43n patients with ST-segment elevation myocardial infarc-
ion (STEMI) survival is strongly dependent on the time to
eperfusion, whether it be mechanical or pharmacological
1–5). Despite potential advantages of primary percutaneous
oronary intervention (PCI), it is not always available and is
sed as the initial reperfusion strategy in only 38% of all
atients presenting with STEMI (6). Fibrinolytic therapy
emains the most common initial therapy for STEMI in the
.S. and worldwide (7–9). For example, 27.6% of all U.S.
atients reported in the NRMI (National Registry of
yocardial Infarction) database in 2006 received fibrino-
ytic treatment (10). An initial fibrinolytic strategy restores
ormal flow (Thrombolysis In Myocardial Infarction
TIMI] flow grade 3) in only about 50% to 60% of STEMI
atients at 90 min (11). Successful pharmacological reperfu-
ion is less commonly achieved in elderly patients and patients
ith cardiogenic shock and is also associated with increased
isk of intracranial bleed in elderly patients (12–14).
Based on limited randomized data, rescue PCI appears
uperior to conservative therapy following incomplete or un-
uccessful fibrinolysis and merits more frequent consideration
15,16). Considering these studies and expert opinion, the
ecent European Society of Cardiology as well as the American
ollege of Cardiology/American Heart Association STEMI
uidelines favor urgent/emergent rescue PCI for many patients
ho fail to (fully) achieve reperfusion by 90 min following
dministration of fibrinolytic therapy (17,18).
The outcomes of rescue PCI have not been well described
n community practice. Randomized trials have been small
nd universally have struggled with difficult enrollment. The
aucity of randomized data is reflected in a recent meta-
nalysis of all 6 randomized rescue PCI trials with a
ombined total of 908 patients (19). Contemporary efforts
o define the incidence and predictors of mortality in this
escue PCI population are lacking in the literature. Further-
ore, only limited information on the major predictors of
his outcome is available. The sheer volume of reported
ases in the NCDR (National Cardiovascular Data Regis-
ry) make it a valuable resource for further examination of
redictors of mortality and for development and validation
f a tool for prediction of an individual’s probability of being
live at the time of hospital discharge following rescue PCI.
Using the NCDR database, we determined the incidence
nd predictors of mortality in STEMI patients undergoing
escue PCI after failed fibrinolytic therapy. We then created a
implified survival prediction tool for this important patient
opulation using 70% of the dataset and subsequently validated
t against the remaining 30% of the dataset.
ethods
ata registry and selection. The NCDR is a national cath-
terization/PCI registry that has data from 811 participating
ospitals. The participating hospitals provide standard data collowing written definitions and abiding by uniform data
ntry and transmission requirements. Submitted data un-
ergo quality checks at NCDR. Details on the data collec-
ion process have previously been published (20,21). The
tudy population consisted of all STEMI patients undergo-
ng rescue PCI in the hospitals contributing to the NCDR
uring the period from January 1, 2004 to March 31, 2008
Table 1).
eﬁnition of rescue PCI. A rescue PCI was identified by
equiring all the following. 1) Admission diagnosis was
TEMI. 2) Operator indicated that the procedure was a
escue PCI, i.e., PCI followed failed fibrinolysis for a patient
ith persistent or recurrent myocardial ischemia (i.e., not a
acilitated PCI). 3) The PCI status was indicated as urgent,
mergent, or salvage (not elective). In addition, patients
ere excluded if more than 2 components among baseline
eatures were missing. This is depicted in Figure 1.
utcomes. The primary outcome event was in-hospital
ortality.
tatistics. Of the data elements in the NCDR data form, 21
f the most plausible, known
isk factors including those as
dentified in previous research
22) or as identified in the com-
ittee’s clinical experience con-
tituted the list of initial candi-
ate predictors (Table 2). The
ariables include: age, sex, Cau-
asian race, body mass index,
lomerular filtration rate (GFR)
modification of diet in renal
isease), renal failure, diabetes,
erebrovascular disease, periph-
ral vascular disease, chronic
ung disease, hypertension, family history of coronary artery
isease, prior myocardial infarction, prior congestive heart
ailure, prior PCI, prior coronary artery bypass graft, New
ork Heart Association functional class, cardiogenic shock,
re-procedural intra-aortic balloon pump, PCI status, and
ymptom onset time to presentation. Multivariate logistic
egression with a backward selection method (p  0.05 to
emain in the model) was then performed to identify
ndependent predictors of mortality. Differences in baseline
haracteristics between derivation cohort and validation
ohort were compared using Wilcoxon 2-sample test for
ontinuous variables and chi-square test for categorical
ariables. With the goal of calculating a mortality risk score,
he cohort was randomly divided into 2 parts: a derivation
et (70% of the data) and a validation set (30% of the data).
issing values were imputed to the lower risk group for
iscrete variables, and replaced with sex, renal failure/
ialysis-specific medians for estimated GFR. In the deriva-
ion set, the associations of rescue PCI for individual
Abbreviations
and Acronyms
CI  confidence interval
GFR  glomerular filtration
rate
GP  glycoprotein
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarctionandidate risk factors with mortality were calculated with
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44ierarchical logistic regression models using generalized
stimating equation (23) that accounted for clustering of
ata by clinical center, and these associations were
resented as odds ratios with 95% confidence intervals
CI). Using a backward variable selection strategy and
linical judgment (criterion for retention in the model,
 0.05), a multivariable hierarchical logistic regression
odel was constructed to determine the independent
redictors of mortality.
isk score. To simplify the scoring tool and to optimize
ts utility, only pre-angiographic variables were consid-
red. Of the remaining variables, the 6 most plausible and
Table 1. Baseline Characteristics
Characteristic
Derivation
Cohort
(n  5,569)
Validation
Cohort
(n  2,438) p Value
Demographics
Age, yrs, median (25th–75th) 57 (50–66) 58 (50–67) 0.09
Male sex 4,191 (75.3) 1,827 (74.9) 0.8
Race 0.9
Caucasian 4,878 (87.6) 2,128 (87.3)
Black 224 (4.0) 93 (3.8)
Hispanic 141 (2.5) 57 (2.3)
Asian 57 (1.0) 31 (1.3)
Native American 31 (0.6) 14 (0.6)
Other 235 (4.2) 111 (4.6)
Risk factors
BMI, kg/m2
18.5 62 (1.1) 24 (1.0) 0.5
18.5 and 30 62 (1.1) 24 (1.0)
30 2,101 (37.7) 904 (37.1)
Previous MI, 7 days 887 (15.9) 375 (15.4) 0.5
Previous CHF 192 (3.5) 83 (3.4) 0.9
Cerebrovascular disease 261 (4.7) 116 (4.8) 0.9
Peripheral vascular disease 258 (4.6) 120 (4.9) 0.6
Chronic lung disease 673 (12.1) 273 (11.2) 0.3
Hypertension 3,197 (57.4) 1,337 (54.8) 0.03
History of tobacco use
Former 1,132 (20.3) 507 (20.8) 0.5
Current 2,810 (50.5) 1,197 (49.1) 0.3
Family history of CAD 1,304 (23.4) 547 (22.4) 0.96
Dyslipidemia 3,238 (58.1) 1,419 (58.2) 0.4
Glomerular ﬁltration rate, ml/min
30 96 (1.7) 45 (1.9)
30 and 60 1,136 (20.4) 505 (20.7)
60 and 90 2,687 (48.3) 1,209 (49.6)
90 1,252 (22.5) 494 (20.3)
Diabetes/control 0.4
Noninsulin diabetes 879 (15.8) 375 (15.4)
Insulin diabetes 226 (4.1) 85 (3.5)
Renal failure 0.8
Nondialysis 85 (1.5) 35 (1.4)
Dialysis 26 (0.5) 9 (0.4)owerful were left in the model. Using the beta coeffi- pients of these 6 variables, a point scoring system was
reated to predict survival to discharge from the hospital
24). Once the risk score was derived, the performance of
his risk prediction tool as a discriminator of actual
ortality was assessed in the remaining 30% of the data
validation set). Mortality discrimination in the valida-
ion set for this model was determined by the use of the
-statistic. All comparisons were 2-tailed, and a p value
0.05 was considered statistically significant. All statis-
ical analyses were performed by the Duke Clinical
esearch Institute using SAS software (version 9.0, SAS
nstitute, Cary, North Carolina).
esults
total of 166,516 patients undergoing PCI following a
resentation of STEMI were reported from the 811
articipating hospitals between January 1, 2004, and
arch 31, 2008 (Fig. 1). The final study cohort consisted
f 8,007 STEMI patients being treated with PCI in a
escue mode after a failed initial fibrinolytic strategy.
Facilitated” PCI patients without rescue criteria were
ot included. Within this strictly defined rescue PCI
ohort, 464 (5.8%) expired during the index hospital
dmission.
emographic and clinical characteristics. Demographic and
linical characteristics are shown in Table 1. Most
Table 1. Continued
Characteristic
Derivation
Cohort
(n  5,569)
Validation
Cohort
(n  2,438) p Value
Cardiac status
Previous PCI 849 (15.3) 365 (15.0) 0.8
Previous CABG 254 (4.6) 117 (4.8) 0.6
NYHA functional class
IV 3,467 (62.3) 1,543 (63.3) 0.8
III 851 (15.3) 360 (14.8) 0.5
Cardiogenic shock 643 (11.6) 270 (11.1) 0.2
Period of symptom onset
to admission
6 h 4,045 (72.6) 1,806 (74.1)
6 h and 12 h 893 (16) 364 (14.9)
12 h and 24 h 356 (6.4) 138 (5.7)
24 h and 48 h 145 (2.6) 73 (3.0)
48 h and 7 days 116 (2.1) 45 (1.9)
Demographic characteristics and risk factors of patients undergoing rescue PCI in the derivation
and validation cohorts, respectively, with p values. Cohort data presented as n (%) unless other-
wise indicated.
BMI bodymass index; CABG coronary artery bypass graft; CAD coronary artery disease;
CHF congestive heart failure; MImyocardial infarction; NYHANewYork Heart Association;
PCI percutaneous coronary intervention.atients were Caucasian men with median age of 58
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45ears. Diabetic patients constituted 19.6% with 15.8%
nd 3.4% of patients having had past history of myocar-
ial infarction and congestive heart failure, respectively.
n 22.3% of patients, GFR 60 ml/min was noted.
dditional clinical characteristics are shown in Table 1.
redictors of mortality. Twenty-one candidate variables
ere considered. Multivariate logistic regression with a
ackward selection method (p  0.05 to remain in the
odel) was then performed to identify 6 independent
redictors of mortality. Table 2 depicts the multivariable
ogistic regression showing independent predictors of
ortality using a generalized estimating equation. Inde-
endent predictors of mortality included: age, GFR,
ardiogenic shock, salvage PCI status, prior congestive
eart failure, and diabetes mellitus requiring insulin. The
rea under the receiver-operator characteristic curve
C-statistic) was 0.88, indicating excellent mortality
iscrimination.
isk score for rescue angioplasty. Table 3 depicts the sim-
lified survival prediction tool developed for this rescue PCI
opulation, the NCDR-RESCUE (Real-World Estimator
f Survival in Catheterized STEMI Patients Following
nsuccessful Earlier Fibrinolysis) score. This tool was
erived from 70% of the dataset and validated against the
Figure 1. Flow Chart of Rescue PCI Patients
Of 166,516 patients who underwent percutaneous coronary intervention (P
rescue PCI. Out of these, 625 patients were excluded for various reasons (n
or missing 2 values among candidate variables). Study cohort consisting
erate a model and a validation (30% of patients) group to predict in-hospit
cular Data Registry.emaining 30% of the dataset, with excellent performance tC-index 0.88). Figure 2A shows a good linear correla-
ion between the observed and predicted mortality.
igure 2B shows the distribution of scores in both the
erivation and the validation groups and the predicted
ortality within various arbitrary score range. The re-
arkable feature of this risk estimator tool is that it
nables the investigator to arbitrarily segregate patients
nto 6 clinically meaningful risk categories based on the
isk score. The numbers of patients in Categories I to VI
ere as follows: 557 (22.8%) in Category I, 1,211 (49.7%)
n Category II, 450 (18.5%) in Category III, 160 (6.6%)
n Category IV, 53 (2.2%) were noted in Category V, and
(0.003%) patients were noted in Category VI. The risk
f mortality in Category I with 0 to 9 points was 0.4%
95% CI: 0.0% to 1.3%). Category II with 10 to 19 points
ad a mortality risk of 1.6% (95% CI: 0.9% to 2.4%).
ategory III accrued 20 to 29 points and a 7.6% (95% CI:
.3% to 10.4%) risk of mortality. Category IV with 30 to
9 points had a mortality risk of 27.5% (95% CI: 20.7%
o 35.1%). The Category V patients accrued 40 to 49
oints and had a mortality risk of 64.2% (95% CI: 49.8%
o 76.9%) whereas the Category VI patients who scored
50 points suffered a risk of mortality of 100% (95% CI:
9% to 100%). The exact risks in both the derivation and
ST-segment elevation myocardial infarction, 8,632 patients underwent
ent/emergent procedures, discharged to other hospital/transitional care,
07 patients was divided into a derivation (70% of patients) group to gen-
rtality. ACC-NCDR  American College of Cardiology National Cardiovas-CI) for
onurg
of 8,0
al mohe validation groups are shown in Figure 2B.
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46iscussion
here is a paucity of data on rescue PCI in community-
ased practice. This is an effort to develop a model for
redicting mortality in this high-risk group to help better
isk stratify patients to achieve optimal outcomes. De-
pite marked increase in primary PCI as the strategy of
hoice for STEMI patients, a significant number of these
atients are treated with an initial thrombolytic strategy
ither due to lack of access to primary PCI or the time
ifference of door-to-balloon from door-to-needle time
eing 1 h. Despite the limitations of fibrinolytic ther-
py compared with primary PCI, data indicate that many
hysicians often do not assess the success of reperfusion
n patients who receive fibrinolysis, and only a minority
avored an interventional strategy in cases of failed
brinolysis (25), possibly due to incorrect perceptions of
he risk/benefit of PCI in this setting.
The main strengths of this study include the large sample
ize, reflection of actual community practice of patients
resenting with rescue PCI, and provision of a robust risk
odel for mortality based on pre-procedural variables. The
ize of the cohort-with 8,007 subjects—increases the pub-
ished outcomes experience on rescue PCI by an order of
agnitude and reflects actual community practice. Obser-
ational in nature, the main strength of the CathPCI
egistry is that its data reflect how clinicians as a group are
ctually negotiating a number of sequential decision nodes
s an integrated function of all inputs, including availability
f limited randomized trial data, extrapolation from related
linical scenarios for which data do exist, and nonclinical
nputs. The study helps the cardiologist to stratify risk into
ifferent categories based on the easily defined pre-
rocedural covariates and will help health care providers,
atients, and families to make informed decisions based on
bjective data. One can predict the probability of an
ndividual being alive to hospital discharge with the
Table 2. Multivariate Predictors of Mortality
Unadjusted
Variable OR Lower (95% CI) Upper (95% CI) p Value
Cardiogenic shock 19.18 14.82 24.81 0.001
Age, per 10-yr increase 1.07 1.06 1.08 0.001
GFR, per 10-U increase 0.95 0.94 0.95 0.001
PCI status  salvage 6.95 4.37 11.05 0.001
Prior CHF 4.24 2.95 6.07 0.001
Insulin-treated diabetes 2.45 1.66 3.63 0.001
Multivariate predictors of mortality based on the initial univariate variables with significant p value
catheterization laboratory or procedure. Variables in the initial models: age, sex, Caucasian race,
vascular disease, chronic lung disease, hypertension, family history of CAD, prior MI, prior CHF, prio
status, symptom onset time to presentation.
CI confidence interval; GFR glomerular filtration rate; other abbreviations as in Table 1.CDR-RESCUE score, which highlights the value of this wovel and now validated prediction tool. A rescue PCI
atient can be placed into 6 meaningful risk groups that
orrespond to clinically important categories of in-hospital
ortality risk, ranging from Category I (0.4%, 95% CI:
.0% to 1.3%) to Category VI (100%, 95% CI: 59% to
00%) with incremental increase in risk for in-between
ategories.
Our findings regarding magnitude and predictors of
isk of mortality in this population are best understood in
he context of prior studies. Difficulty in enrollment has
imited previous studies. The MERLIN (Middlesbrough
arly Revascularization to Limit Infarction) study (26)
howed a significant reduction of the primary composite
nd point— driven by unplanned revascularization rather
han mortality—in the rescue PCI arm compared with
onservative therapy for STEMI patients failing to reper-
use following fibrinolytic therapy. Similarly, the REACT
Rescue Angioplasty Versus Conservative Treatment or
epeat Thrombolysis) trial demonstrated that rescue PCI,
hen compared with repeat fibrinolytic therapy or conser-
ative management, was associated with no mortality ben-
fit but an improvement in the composite of death, rein-
arction, stroke, or severe heart failure (15). In both of these
rials, rescue PCI was associated with increased bleeding,
hich has been demonstrated to be an adverse prognostic
ndicator (15,27,28). The previously reported in-hospital
ortality rate from studies on patients undergoing rescue
ngioplasty including mostly observational nonrandomized
tudies and few randomized data falls within a wide range of
% to 12% (29–33), although direct comparison to our
.8% overall mortality is complicated by differing meth-
dologies in the time of ascertainment of mortality. In
EACT, mortality (6.2%) was measured at 6 months,
nd in MERLIN, at 30 days (9.8%) and at 1 year (14.4%)
15,26,28). The recently published 1-year results of the
EACT trial showed a sustained benefit for RESCUE PCI
Adjusted 
i-Square OR Lower (95% CI) Upper (95% CI) p Value Chi-Square
504.5 12.66 9.55 16.78 0.001 312.3
172.8 1.64 1.45 1.86 0.001 63.28
270.6 0.74 0.68 0.81 0.001 47.24
67.32 3.58 2.31 5.57 0.001 32.27
61.67 2.07 1.23 3.47 0.006 7.54
20.08 2.09 1.23 3.54 0.006 7.46
) in the derivation cohort (n 5,569). Salvage indicates any cardiopulmonary resuscitation before
R (modification of diet in renal disease), renal failure, diabetes, cerebrovascular disease, peripheral
rior CABG, NYHA functional class, cardiogenic shock, pre-operation intra-aortic balloon pump, PCICh
s (0.05
BMI, GF
r PCI, pith mortality rate of 11.2% in this high risk group
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47ompared with 22.3% in the repeat thrombolysis and 22.4%
n conservative treatment groups (34).
The factors that may have favorably influenced mortality in
ur study may reflect certain technical advances and other
hifts in PCI practice patterns since the time of enrollment in
ERLIN and REACT. In our patient population, 59%
eceived glycoprotein (GP) IIb/IIIa inhibitor and 92.6% re-
eived stents; in the positive REACT trial (15), 43.4% of
atients received GP IIb/IIIa inhibitors and 68.5% received
tents. In contrast, in the negative MERLIN trial, 3.3%
eceived GP IIb/IIIa inhibitors and only 50.3% received stents
28). The practice patterns have possibly shifted toward greater
Table 3. The NCDR-RESCUE Score
Variable Points
Presence of cardiogenic shock
Yes 16
No 0
Age, yrs, per 10-yr increase
30 0
30–39 3
40–49 6
50–59 9
60–69 12
70–79 15
80–89 18
90–99 21
GFR, per 10-U decrease, ml/min
90 0
80–89 1
70–79 3
60–69 5
50–59 6
40–49 8
30–39 10
20–29 12
10–20 14
10 16
Salvage status, any CPR
Yes 8
No 0
Prior CHF
Yes 4
No 0
Diabetes mellitus treated with insulin
Yes 5
No 0
Example: 68-year-old nondiabetic patient with GFR  50 ml/min and no prior history of CHF,
presentingwith cardiogenic shock and no CPR has been administered: NCDR-RESCUE score 12
 6 16 (0) (0) (0) 34. Figure 2B facilitates conversion of score to absolutemortality risk.
CPR  cardiopulmonary resuscitation; NCDR-RESCUE  Real-World Estimator of Survival in
Catheterized STEMI Patients Following Unsuccessful Earlier Fibrinolysis score for predicting sur-
vival to hospital discharge in patients presenting for rescue PCI; other abbreviations as in Tables 1
and 2.P IIb/IIIa inhibitor usage in response to data showing lower wortality using abciximab (vs. no abciximab) in the setting of
escue PCI (35,36). The patient population we studied was
uch sicker and included 4.9% who had undergone any
ardiopulmonary resuscitation and 11.4% with cardiogenic
hock. Both of these conditions were exclusions from the
EACT trial and presumably in MERLIN trial, although the
nvestigators did not report this.
Comparing the current predictive model to a previous
TEMI-population predictive model derived from the
ADILLAC trial (37) in primary PCI, there are remark-
ble similarities. Although the presence of renal insuffi-
iency, age, and history of congestive heart failure are
ommon to both models, we excluded post-angiographic
ariables in the calculation of the NCDR-RESCUE score
o improve its usefulness in the clinical setting. An individ-
alized risk assessment can be invaluable in guiding patient
nd family discussion and setting realistic expectations of
utcome.
Each of the final 6 inputs to our RESCUE survival
rediction tool also has a sound basis in the published
iterature as a mortality predictor in similar or related
linical settings. Cardiogenic shock provides the strongest
djusted odds ratio (12.7) of the simplified model’s 6 final
nput variables, which is consistent with the PCI arm in
HOCK (Should We Emergently Revascularize Occluded
oronaries for Cardiogenic Shock?) trial (38). Age was an
mportant and powerful independent predictor of mortality
n our study, which is consistent with previous studies
39,40). Impaired renal function, as reflected by a dimin-
shed estimated GFR calculated from a single creatinine
easurement, was also a notably potent predictor of mor-
ality similar to the GRACE (Global Registry of Acute
oronary Events) registry (41). Diabetic status and prior
iagnosis of congestive heart failure each contributed inde-
endently as well, although to a modest extent when
ompared with the other 4 factors in agreement with
ublished reports (40). In the subgroup of patients who have
ndergone any cardiopulmonary resuscitation before PCI
salvage status), PCI was another independent predictor of
ortality in our final simplified model. The negative impact
f the need for cardiopulmonary resuscitation on the pa-
ient’s likelihood of survival to discharge from the hospital is
ot unanticipated and has been documented in numerous
atient subsets (42).
This study from the NCDR registry is the largest series of
atients undergoing rescue angioplasty. The dataset pro-
ides a real-world estimate of mortality in contemporary
ractice including use of stents, GP IIb/IIIa antagonist, and
hienopyridine with beta-blockers, statins, and angiotensin-
onverting enzyme inhibitors. There has been recent pub-
ished data of overall mortality prediction from the NCDR
opulation for patients undergoing PCI (22). However, we
elieve that the rescue PCI population dataset is unique and
arrants a separate model that would facilitate providers to
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48ake clinical decisions. This is reinforced by the overall
n-hospital mortality of 5.8% with a wide range from 0.4%
o 100% depending on patient characteristics predicating
he requirement of a tool such as this to provide individu-
lized risk estimation for patients who fail to reperfuse after
brinolytic therapy. Personalized risk information of this
ort can be invaluable in guiding triage decisions and
iscussions with patients, families, and colleagues. It is our
ope that this tool may prevent the lack of an appropriate
eferral for a potentially life-saving rescue PCI procedure
Figure 2. Correlation of Predicted Versus Observed Mortality and NCDR Re
(A) Predicted mortality versus observed mortality in the derivation versus valid
correlation. (B) For individual patients, the points are calculated to predict in-h
ﬁdence interval (CI). Abbreviations as in Figure 1.ecause of an incorrect perception of mortality risk. ttudy limitations. Although this is the largest reported
xamination of mortality predictors in the rescue PCI
opulation, it is fundamentally derived from a self-
eported retrospective cohort registry, without indepen-
ent core laboratory assessment of angiographic variables.
ecause only in-hospital mortality was captured and 3.7%
f the cohort was transferred to another facility following
escue PCI, uncertainty is introduced around our re-
orted overall mortality risk of 5.8%. In paired sensitivity
nalyses—assuming 0% or 100% mortality following
Score Used To Predict In-Hospital Mortality
cohorts in rescue percutaneous coronary intervention patients shows a good
l mortality as described in legend of Table 3. Data are shown with 95% con-scue
ation
ospitaransfer— overall mortality boundaries were 5.6% to
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49.6%. However, assuming 100% mortality for transferred
atients failed to appreciably change the multivariable
odel. The ability of the novel RESCUE survival pre-
iction tool to predict outcomes beyond hospital dis-
harge remains unexamined. Also unattainable was in-
ormation regarding the outcomes of patients who were
anaged without a catheterization laboratory. In addi-
ion, the study was observational in nature and unmea-
ured confounders cannot be excluded. Finally, these
ndings have not been validated against other databases
utside of the NCDR CathPCI population, as no other
uitable comparator dataset on this important patient
roup exists.
onclusions
verall risk of in-hospital mortality among patients under-
oing rescue PCI in the NCDR CathPCI registry is 5.8%
95% CI: 4.8% to 6.7%). Within this population of STEMI
atients who have failed to clinically reperfuse, it is possible
o quickly and easily place an individual patient into 1 of 6
isk categories with mortality range between 0.4% in Cat-
gory I to 100% in Category VI using the NCDR-
ESCUE tool, derived from only 6 clinical input variables,
ll readily discernable before angiography. This NCDR-
ESCUE tool has the potential to quickly and accurately
rovide the clinician with critical prognostic information to
nform, triage, and guide patient and family discussions for
his important and vulnerable population.
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